SU1237214A1 - Vaccine for prophylaxis of larval infestations with taenia of farm animals - Google Patents

Description

The invention relates to veterinary parasitology, namely, to obtain a vaccine for the specific prevention of sheep coenurosis.

The purpose of the invention is to improve the effectiveness of the prevention of coenurosis.

Example 1. The starting material for the manufacture of a vaccine is obtained from the mature segments M.multiceps. The segments break and wash the eggs,

The washed M.multiceps eggs in the amount of 50-100 thousand are successively passed through artificial gastric juice (5 ml) for 1.5-2 hours and intestinal (5 ml) juice for 12-15 minutes at 37-38 ° C

The released oncospheres are washed from intestinal juice by culture medium, in which (40-50 ml) culture takes place within 46-48 hours at 37-38 C. Culture medium is prepared from, ml: native serum of 2-3 months body 50 (10%). benzylpenicillin potassium salt 0.135 (0.5 g of dry matter diluted in 10 ml of medium 199). -0.027% streptomycin sulfate 0.09 (0.5 g of dry matter diluted in 1.0 ml of medium 199) -0.018% and medium 199 the rest is up to 500 ml.

After expiration of the cultivation of oncospheres (during this time they turn into the initial stages of tsener-so-c), they are counted and brought to 1900-2100 copies in 1 ml of medium, taking into account the subsequent addition of merthyolite and aluminum hydroxide.

Merthiolt is administered to the vaccine in a 1: 10,000 ratio. those. 0.045 ml is added (1 g of dry matter is diluted in 1.0 ml of medium 199) - 0.009%.

Aluminum hydroxide is added at the rate of 50 ml (6% gel) to 450 ml of the preparation (10%). The finished vaccine is thoroughly mixed, poured into vials or ampoules, monitored for activity, safety and sterility.

The vaccine retains immunogenicity for at least 1-3.5 months at a storage temperature of 4-6 C,

Immunogenicity of the vaccine is controlled by the reaction of latex-agglutinin (RLA) for antibody titer in the blood serum of experimental animals. Antibody titer read satisfactory with positive results

142

tata RLA when diluting serum

1:32 and 1:64.

Immunity intensity is checked by experimental infection of immunized animals.

Example 2. The process is carried out according to Example 1. Composition of medium components,%:

Blood serum 2-3 months t 65 ml13

Benzylpenicillin potassium salt 0.145 ml (0.5 g of dry matter is diluted in 10 ml of medium 199) O ,, 029

Streptomycin sulfate 0.95 ml (0.5 g of dry matter diluted in 1.0 ml of medium 199) 0.019 Merthiol 0.047 ml (1 g of dry matter diluted in 1.0 ml of medium 199) 0.0095 Aluminum hydroxide 65 No. (6% gel) 13

Example 3. The process is carried out according to Example 1. Composition of medium components,%:

Blood serum 2-3 months old 75 ml 15 Benzplpenicillin potassium salt 0.15 ml (0.5 g of dry matter diluted in 10 ml of medium 199) 0.03

Streptomycin sulfate 0.1 ml (0.5 g dry weight: diluted with 1.0 ml of medium 199) 0.02 Merthiol 0.05 ml (1 g of dry matter diluted with 1.0 ml of medium 199) 0.01

Aluminum hydroxide 75 ml (6% gel) 15 P 5 n measures 4-1 1. The process is carried out as in example 1, however, the quantitative content of one of the components is selectively changed, namely: the amount of serum is reduced to 9%, the benzylpenicillin potassium salt, co 0.025%, streptomycin suldo 9% or their amount is increased to 16, 0.04 , 0.03 and 16%.

90-95

Separate

The absence of

Single Hfcie

The absence of

ten

eleven

As can be seen from the table, a decrease in the blood serum content of the bodies does not provide developing nutrients with sufficient nutrients, which leads to a slowdown in their growth, and an increase in the blood serum does not lead to a noticeable increase in growth, but only increases the amount of whey proteins in the vaccine. which do not fulfill an immunogenic role. A decrease in the content in the culture medium of benzylpenicillin or streptomycin sulfate leads to the appearance of colonies of banal microflora, and an increase in the content of both drugs causes inhibition of developing processions. Merthiol t is introduced into the culture only after the end of the cultivation of the processus for conservation in quantity.

Com ported according to examples 1-11 are shown in the table.

32-64

32-64 32-64

12

12

12

16-32

ten

32-64

12

0.01% relative to the volume of the medium. Such content for this preparation is optimal, the most gentle and does not cause destruction of the preserved objects. An increase in the content of aluminum hydroxide does not have a noticeable effect on the timing of the effect of the vaccine on the immune system of animals, and in some cases there is a formation of hardening that is not absorbed for a long time. Reducing the amount of aluminum hydroxide reduces the time it takes for the vaccine to affect animals.

To prepare a series of vaccines, it is necessary to treat M.multiceps with gastric and intestinal juices, in the course of which the oncospheres are released from the membranes.

The resulting vaccine is used internally from the inside of the poor-.

5123721A6

pa in doses of 1 ml per head doubled Immunity in vaccinated animals

with an interval between injections, 9-comes after 25-30 days after

10 days. Immunization is harmed. The duration of immuniT-1, 5 months to pasture on pasture. For at least a year.

Claims (1)

VACCINE FOR PREVENTION OF LARVAR TENIIDOSIS OF AGRICULTURAL ANIMALS, containing a two-day culture of larvocysts and a nutrient medium based on 19D medium and blood serum, characterized in that, in order to increase the effectiveness of prophylaxis of cenurosis, it additionally contains potassium hydrochloride and aluminum hydrochloride streptomycin sulfate, and as a larvocyst culture Multiceps multi- ceps in the following ratio, vol.%: Blood serum 10-15 Benzylpenicillin on potassium salt 0,027-0,03 Streptomycin sulfate 0.018-0.02 Merthiolate 0.009-0.01 Hydroxide' aluminum 10-15 Wednesday 199 Rest Two day ω culture larvo- Multi- cyst czz ceps multi- ceps 1.9 Ί0 ⁶ - χ, 2.1 · 10 copies / 1 ml vaccines> serum dilution theta RLA 1:32 and 1:64. namely to